刘新华，二级教授

研究方向：新药分子设计、合成及生物活性研究

电子邮箱：xhliuhx@163.com

办公室：知行楼B1109

个人简介：

药物化学博导，享受省政府津贴。先后毕业于合肥工业大学、贵州大学(硕士)、南京大学(博士)，新加坡南洋理工大学访问教授。皖江学者、安徽省学术与技术带头人、安徽省杰青。先后主持国家973专项、主持国家自然科学基金5项；主持完成安徽省重大科技专项。安徽省药物化学专委会首届主任委员，安徽省首届高水平导师。主持完成10多个新药临床前评价、在国内首次成功仿制三类新药2项、主持制定国家新药标准2项。以第1获奖人获安徽省自然科学二等奖1项、安徽省科技进步三等奖2项。

学术兼职2020/01-至今，Medicinal Chemistry编辑

2020/01-至今，Current Topics in Medicinal Chemistry编委

2018/01-至今，安徽省药物化学专委会主任委员2018/01-至今，安徽省药学会常务理事

科研项目：

(1)靶向Cat C的新型非肽基非共价抑制剂：优化设计合成及抗炎活性作用机制(22377001), 2024.1~2027.12，国家自然科学基金面上项目, 60

(2)靶向Dyskerin-NOP10相互作用的特异性小分子：优化设计合成及抑制端粒

酶活化(21977001), 2020.1~2023.12，国家自然科学基金面上项目, 66

(3)抗肿瘤药物合成的关键技术与产业化研究(18030801118),安徽省重大科技

专项, 2018.1~2020.12，360

(4)选择性识别端粒蛋白p65的苯并吡喃新先导：优化设计合成及作用机制,(21572003), 2016.1~2019.12，国家自然科学基金面上项目, 78

(5)基于端粒酶TERT靶标新先导的设计合成与机制研究, 2014.1~2016.12,安徽省杰出青年基金，30

(6)新型端粒酶TERT抑制剂：手性吡唑-香豆素-色酮新骨架的优化设计合成及构效关系(21272008), 2013.1~2016.12，国家自然科学基金面上项目, 80

(7)新型以手性2H吡唑-噁唑为中心多杂环的设计、杀菌活性及构效关系(20902003)，2010.1~2012.12，国家自然科学青年基金，19

发表论文情况：

(1)Duo Ma, Xianan Liu, §Xingxing Zhang, Yaling Hong, Yumeng Wang, Famin Zhang, Leran Du, Junjie Zhao, Quan Wang, Cui Chang, Wenhu Liu, Yan Lou,Xinhua Liu*, Discovery of the 2, 3-dihydrobenzopyrane-4-one as a Potent FTO Inhibitor Against Obesity-related Metabolic Diseases,Journal of Medicinal Chemistry,2025,doi.org/10.1021/acs.jmedchem.4c03124

(2)Ya-Xi Ye, Jian-Cheng Pan, Hai-Chao Wang, Xing-Tao Zhang*, Hai-Liang Zhu*,Xin-Hua Liu*, Advances in small-molecule fluorescent probes for the study of apoptosis,Chemical Society Reviews,2024,53, 9133-9189.

(3)Yao Yao Yan, Xing Xing Zhang, Yun Xiao, Xiao Bao Shen, Yu Jie Jian, Yu Meng Wang,Zi Hao She, Ming Ming Liu*andXin Hua Liu*,Design, Synthesis of 2-amino-pyridine Derivative As a Potent CDK8 Inhibitorfor Anti-colorectal Cancer Therapy,Journal of Medicinal Chemistry,2022,65,13216-13239.

(4)Xing Xing Zhang,Yun Xiao,Yao Yao Yan, Yu Meng Wang, Han Jiang, Lei Wu, Jing-bo Shi,*andXin Hua Liu*,Discovery of the Novel 1H Pyrrolo[2,3 b]pyridine Derivative as a Potent Type II CDK8 Inhibitor against Colorectal Cancer,Journal of Medicinal Chemistry,2022,65,12095-12123.

(5)Yaoyao Yan, Chen Xing, Yun Xiao, Xiaobao Shen, Zhaoyan Zhang, Chuanbiao He, Jing Bo Shi, Mingming Liu*,Xinhua Liu*, Discovery and Anti-inflammatory Activity Evaluation of Novel CDK8 Inhibitor through Up-regulation of IL-10 for Treatment of Inflammatory Bowel Diseaseinvivo,Journal of Medicinal Chemistry,2022,65, 7334-7362.

(6) Liu Zeng Chen, Xing Xing Zhang, Ming Ming Liu, Jing Wu, Duo Ma, Liang Zhuo Diao, Qingshan Li,Yan Shuang Huang, Rui Zhang, Ban Feng Ruan* andXin Hua Liu*, Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis,Journal of Medicinal Chemistry,2021,64, 13633-13657.

(7)Xing Chen, Yaoyao Yan, Zhaoyan Zhang, Faming Zhang, Mingming Liu, Leran Du, Haixia Zhang, Xiaobao Shen, Dahai Zhao, Jing Bo Shi,* andXinhua Liu*, Discovery and InVivo Anti-inflammatory Activity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor, Journal of Medicinal Chemistry,2021,64, 11857-11885.

(8) Yang Wang, Xing Chen, Yaoyao Yan, Ming ming Liu* andXin Hua Liu*, Discovery and SARs of 5-chloro-N4-phenyl-N2-(pyridin-2-yl) pyrimidine-2,4-diamine derivatives as oral available and dual CDK 6 and 9 inhibitors with potent anti-tumor activity,Journal of Medicinal Chemistry,2020, 63, 3327-3347.

(9)Mingming Liu, Yuru Liang, Zhongzhen Zhu, Jin Wang, Xingxing Cheng, Jiayi Cheng, Binpeng Xu, Rong Li,Xinhua Liu* and Yang Wang*, Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-inducible Factor (HIF) 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis,Journal of Medicinal Chemistry,2019,62, 9299-9314.

(10)Jing Bo Shi, Liu Zeng Chen, Bao Shi Wang, Xin Huang, Ming Ming Jiao, Ming Ming Liu, Wen-Jian Tang andXin-Hua Liu*, Novel Pyrazolo[4,3-d]pyrimidine as Potent and Orally Active Inducible Nitric Oxide Synthase (iNOS) Dimerization Inhibitor with Efficacy in Rheumatoid Arthritis Mouse Model,Journal of Medicinal Chemistry,2019,62, 4013-4031.

获奖情况：

(1)刘新华等，靶标端粒酶hTERT的新型活性分子的设计合成与作用机制，安徽省自然科学二等奖,Z-2020-2-026-R1. 2020年

(2)刘新华等，基于靶标与机制的新型抗炎活性分子的设计合成，安徽省自然科学三等奖, Z-2023-2-037-R1. 2023年

(3)刘新华等，具有药用价值的新型杂环小分子的设计合成与生物活性研究,安徽省自然科学三等奖, 2014-3-R1,2014年

(4)第十五届安徽青年科技奖，2013年

专利情况：

(1)刘新华;石静波;陈冉;王宝石;汤文建;陈留赠;汪洋;一种嘧啶并吡唑杂环化合物、制备方法、用途，专利号：ZL 2017 1 1446400.5；2020.2.18

(2)刘新华，石静波，胡阳生，陈刘赠，刘明明，黄馨，王宝石，韩旭，焦明鸣；丹皮酚衍生物、药物制剂、制备方法与应用；专利号：ZL 2019 1 1329122.4；2023. 3. 21

(3)刘新华，石静波；一种5-氯-嘧啶-2,4-二胺类化合物及其制备方法和应用；专利号：ZL 2020 1 0241722.1；2023. 5. 9

(4)刘新华，刘明明，石静波，闫尧瑶，张兴星，王宇蒙，肖云江瀚，佘梓濠，吴磊；一种芳基脲类衍生物及其制备方法与应用；专利号：ZL 2022 1 0891463.6；2023. 6. 27

(5)刘新华，石静波，朱仁德，吴静，胡阳生，张昭燕；一种丹皮酚衍生物及其制备方法、制剂与应用；专利号：ZL 2021 1 0758936.0；2023. 3. 7

(6)刘新华，石静波，刘明明，张昭燕，陈星，闫尧瑶，肖云；一种5-取代的嘧啶二胺类衍生物及其制备方法与应用；专利号：ZL 2022 1 0296353.5；2023. 11. 24

(7)刘新华，刘明明，石静波，陈星，闫尧瑶，肖云，张照燕；一种汉黄芩素衍生物及其制备方法与应用；专利号：ZL 2022 1 0379930.7；2023. 11. 24

(8)刘新华，陈星，石静波，刘明明，闫尧瑶，张照燕，张发敏，一种嘧啶-2,4-二胺类化合物及其制备方法与应用；专利号：ZL 2021 1 0129457.2；2024. 3. 1

(9)刘新华，石静波，刘明明，张兴星，闫尧瑶，王宇蒙，肖云，江瀚，佘梓濠，吴磊，一种3-芳杂环取代苯基衍生物及其制备方法与用途，专利号：ZL2022 1 0891482.9；2024. 3. 26